Stockscreener 앱 받기
5.66
0.53%
0.03
시간 외 거래:
5.67
0.010
+0.18%
Mannkind Corp 주식(MNKD)의 최신 뉴스
(02/13/26) Top Picks 2026: MannKind Corp. (MNKD) - moneyshow.com
MannKind (NASDAQ:MNKD) Shares Cross Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Can MannKind Corporation stock double in the next yearLong Setup & AI Powered Market Entry Strategies - mfd.ru
MannKind (MNKD) Begins Enrollment for Pediatric Diabetes Study - GuruFocus
MannKind enrolls first patient in pediatric inhaled insulin study - Investing.com
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D) - Yahoo Finance
MannKind Corp Is Suddenly Everywhere – But Is MNKD Actually Worth Your Money? - AD HOC NEWS
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
Fund Flows: Whats the beta of MannKind Corporation stockWeekly Gains Summary & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Benzinga
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Investing News Network
Analysts Offer Insights on Healthcare Companies: Humana (HUM), MannKind (MNKD) and Inspire Medical Systems (INSP) - The Globe and Mail
MannKind stock gets Buy rating reaffirmation from Truist at $9 target - Investing.com
FDA approves updated dosing guidelines for MannKind’s inhaled insulin By Investing.com - Investing.com Canada
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets - Cantech Letter
Avant Technologies Leads Transformation in Healthcare Market - Intellectia AI
MannKind (NASDAQ:MNKD) Receives Buy Rating from HC Wainwright - MarketBeat
HC Wainwright & Co. Reiterates 'Buy' Rating for MNKD with $11 Ta - GuruFocus
MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy - Finviz
MNKD Stock Gets A Pre-Market Boost From FDA Label Revision For Afrezza - Stocktwits
Why Did MNKD Stock Jump Over 7% In Pre-Market Today? - Asianet Newsable
MannKind stock rises after FDA approves updated Afrezza label By Investing.com - Investing.com Canada
MannKind stock rises after FDA approves updated Afrezza label - Investing.com
FDA approves updated dosing guidelines for MannKind’s inhaled insulin - Investing.com
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy - ChartMill
MannKind’s Volatile Week: Can MNKD Justify The Recent Rebound In Its Stock? - AD HOC NEWS
Growth Report: What hedge funds are buying MannKind CorporationJuly 2025 Levels & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Investment Recap: Is MannKind Corporation backed by strong institutional buying - baoquankhu1.vn
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema - Finviz
Will 2026 FDA Decisions on Afrezza and FUROSCIX Redefine MannKind's (MNKD) Narrative - Yahoo Finance
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - Finviz
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
Short Interest in MannKind Corporation (NASDAQ:MNKD) Grows By 26.1% - MarketBeat
MannKind Corporation (MNKD) Reveals 2026 Growth Drivers - Insider Monkey
MannKind (NASDAQ:MNKD) Shares Down 6.4%Here's What Happened - MarketBeat
Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia - Finviz
CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why - Finviz
Evaluating MannKind (MNKD) Valuation After Recent Share Price Swings And Long Term Return Profile - Yahoo Finance
TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results - Finviz
MannKind (NASDAQ:MNKD) Raised to Strong-Buy at Zacks Research - MarketBeat
MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Deltec Asset Management LLC Takes $3.89 Million Position in MannKind Corporation $MNKD - MarketBeat
Mannkind’s chief people officer sells $297k in stock By Investing.com - Investing.com Nigeria
MannKind Corporation (NASDAQ:MNKD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Insider Sell: Stuart Tross Sells 47,006 Shares of MannKind Corp (MNKD) - GuruFocus
Mannkind’s chief people officer sells $297k in stock - Investing.com
MannKind Corp stock hits 52-week high at 6.33 USD By Investing.com - Investing.com Nigeria
Pharma news weekly roundup - The Pharma Letter
Is MannKind Corporation stock affected by interest rate hikesMarket Trend Review & Consistent Profit Alerts - ulpravda.ru
How MannKind Corporation stock reacts to Fed rate cutsJuly 2025 Snapshot & Safe Swing Trade Setups - ulpravda.ru
Why MannKind Corporation stock is favored by top institutions2025 Biggest Moves & High Yield Equity Trading Tips - ulpravda.ru
Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report - Stocktwits
Boeing’s CEO Tells Staff ‘Important Work Ahead’ To Continue Its Turnaround: Report - Stocktwits
MannKind Rallies On Optimism Of Two Imminent Product Launches: Analyst Sees ‘Multiple Headwinds’ For Stock In 2026 - Stocktwits
How MannKind Corporation stock reacts to global recession fears2025 Volatility Report & Risk Managed Trade Strategies - Улправда
MannKind stock jumps on 2026 catalysts - Investing.com
1.12%
0.87%
자본화:
|
볼륨(24시간):